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The Simian Virus 40 (SV40) small-t antigen (ST) plays an important role in driving cell proliferation, enhancing transformation by the
large-T (LT) antigen. Potential targets of ST are the cyclin kinase inhibitor p27 and the cyclin A gene itself. Transactivation of the cyclin A
promoter by ST depends on the interaction of STwith protein phosphatase 2A (PP2A) and occurs through a cell cycle-regulated E2F site near
the transcription start site of the promoter. A third SV40 early protein, 17KT, also transactivates the cyclin A promoter but, in this case,
transactivation depends on the dnaJ domain of the protein.
D 2004 Elsevier Inc. All rights reserved.
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The contributions of the Simian Virus 40 (SV40) small-t
(ST) antigen to cellular transformation were only fully
appreciated as studies of SV40 moved into human cell
systems. Both LT and ST are required to transform human
fibroblasts (Chang et al., 1985; DeRonde et al., 1989; Ozer
et al., 1996; Porras et al., 1996), but the domains of ST
critical for this function have been explored only recently
(Porras et al., 1996). The requirement for ST in trans-
formation is more stringent in human cells than in rodent
cells, and ST is required to induce both focus formation and
anchorage-independent growth. This joint requirement is
mirrored by the stimulation of cell cycle progression by
SV40 (Rundell et al., 1998), where LT and ST are both
needed to overcome cell cycle inhibition. Density-arrested
fibroblasts only escape contact inhibition when LT and ST
cooperate to lower the cyclin-dependent kinase inhibitors
p21 and p27, respectively (Porras et al., 1999). Studies on
the role of ST in human cell transformation have now been0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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et al., 2001).
The effects of ST on host cells are primarily mediated by
its regulation of protein phosphatase 2A (PP2A) (Kami-
bayashi et al., 1992; Yang et al., 1991). ST sequences
between residues 97 and 103 are involved in binding the
PP2A-A subunit, and mutations like C103S have been used
extensively to study this ST function (Mungre et al., 1994;
Porras et al., 1996; Yu et al., 2001). Indeed, the ability of ST
to interact with PP2A has been found to be critical in all ST-
dependent transformation systems tested to date (Hahn et
al., 2002; Mungre et al., 1994; Porras et al., 1996; Yu et al.,
2001). Generally, ST binding reduces enzymatic activity
leading to an increase in the levels of active, phosphorylated
forms of key cellular proteins, e.g., MAPK, the Na/H-
antiporter, and AKT (Howe et al., 1998; Sontag et al., 1993;
Yuan et al., 2002). MAPK and AKT have several important
downstream targets. For example, ST can drive transcription
of AP1-regulated promoter constructs (Frost et al., 1994) in
a MAPK-dependent fashion, as illustrated in studies of the
cyclin D1 promoter (Watanabe et al., 1996).
ST also contains a dnaJ domain within amino-terminal
sequences that are shared with LT (Kelley and Georgopoulos,05) 596–601
Fig. 1. Diagram of SV40 early region products. In this diagram of the SV40
early region proteins, bold-faced lines represent the coding regions of each
protein, ST, 17KT, and LT (total amino acid content for each protein is
indicated, and lines are not drawn to scale). Dashed lines indicate the
introns that are removed from the common precursor mRNA for these
proteins. Non-coding regions of the transcripts are shown by thin lines. The
general positions of the dnaJ domain (J), PP2A, and RB binding sites are
indicated below the bold-faced lines.
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the Rb family members, p130 and p107, for degradation
(Stubdal et al., 1996, 1997), resulting in the relief of
repression by Rb family members and enhanced cell
proliferation. Recently, it was recognized that SV40 encodes
a 17KT protein (Zerrahn et al., 1993) and that this protein also
targets p130 for degradation and promotes cell proliferation
(Boyapati et al., 2003). No clear role has been assigned to the
dnaJ domain in ST although an earlier study suggested that
this domain might function in the transactivation of the cyclin
A promoter (Porras et al., 1996). In this report, we reevaluate
this study based on our current understanding that the 17KT
protein is expressed from some plasmids thought to encode
ST alone. We now report that both ST and the 17KT protein
can transactivate this promoter, ST in a PP2A-dependent
fashion and 17KT through the dnaJ domain. In addition, the
site in the cyclin A promoter that responds to STwas mapped
to an E2F site previously identified as a cell cycle-regulated
element (Schulze et al., 1995).Results and discussion
Early studies of human fibroblasts infected with recombi-
nant adenoviruses demonstrated that ST alone can increase
levels of cyclin A protein in cells, even when cell cycle
progression continues to be restricted by p21 (Porras et al.,
1999). This increase was reflected in the levels of cyclin A
mRNA. Moreover, the ST-expressing plasmid pw2t
increased transcription from reporter constructs that con-
tained the cyclin A promoter. Surprisingly, initial studies
using pw2t C103S suggested that PP2A interaction was not
involved in ST-induced transactivation of the cyclin A
promoter. Rather, the dnaJ domain found in amino-terminal
sequences shared by ST and LT appeared to be responsible
because a ST-expressing plasmid harboring a mutation in
this domain, pw2t 43/45 (P43L/K45N), showed reduced
transactivation (Porras et al., 1996). It was hard to reconcile
these findings with the fact that the PP2A-binding domain,
but not the dnaJ domain, of ST was required to drive cell
cycle progression in the presence of LT when both SV40
proteins were individually expressed from recombinant
adenoviruses (Rundell et al., 1998).
Some of the inconsistencies we found in the pattern of
transactivation now appear to reflect the expression of a
third SV40 early region product, the 17KT protein (Zerrahn
et al., 1993). As shown in Fig. 1, 17KT is a small protein
which resembles LT in having dnaJ and Rb binding
domains, but a second splice in the message alters the
reading frame of the protein thus deleting most of the
carboxyterminal sequences found in LT. The need to
examine a role for 17KT in cyclin A transactivation was
first indicated by experiments comparing two plasmids,
pw2t and pw2tDL888 (pw2tDL), in which the splice donor
for ST mRNA is deleted, totally eliminating ST expression.
Before the discovery of the 17KT protein, we believed thatthe pw2tDL plasmid did not express any SV40 proteins.
However, as shown in Fig. 2A, both plasmids activated
transcription of the luciferase gene from the 8.1 Kb cyclin A
promoter. Furthermore, transactivation by pw2tDL was
nearly eliminated by mutation of the LXCXE motif to
which Rb family members bind (Fig. 2B, pw2tDLRb-).
These findings, and parallel studies of the behavior of these
constructs in transformation assays, led us to reinvestigate
SV40 protein expression by pw2tDL (Boyapati et al., 2003).
No SV40 proteins were found in pw2tDL-transfected cells
by 35S-labeling or Western blotting. However, 32P-labeled
cells were found to express low levels of a 17KT
phosphoprotein, as described by Zerrahn et al. (ST itself is
not a phosphorylated protein).
The transactivation of the cyclin A promoter by pw2tDL
suggested that the 17KT protein might be responsible. This
possibility seemed likely because 17KT resembles LT in
having dnaJ and pRb binding domains, and LT is a good
transactivator of the cyclin A promoter as well (Beachy et
al., 2002). In addition, we showed that 17KT could alter
stability of the Rb family member, p130, and drive cell cycle
progression in the absence of other viral proteins (Boyapati
et al., 2003). Thus, 17KT resembled the better studied LT
protein in these activities (Stubdal et al., 1996, 1997). To
study ST and 17KT proteins individually, we developed
cDNA derivatives of each protein (Boyapati et al., 2003).
These constructs showed that either ST or 17KT could
activate transcription from the cyclin A promoter (Fig. 3A).
Furthermore, transactivation by the 17KT was dependent on
the dnaJ region of this protein and was significantly reduced
by the 43/45 mutation. It was also reduced by mutation of
the Rb binding motif (data not shown). In these experi-
ments, we used a 17KT cDNA derivative that also contains
an intron upstream of the ATG translational start site. This
construct was derived previously because we were unable to
detect 17KT protein from a cDNA construct in the absence
of an intron. Although not shown here, we confirmed that
the 43/45 dnaJ mutation eliminated transactivation by
pw2tDL as well, consistent with the idea that the 17KT
Fig. 2. Transactivation of the cyclin A promoter by pw2t constructs. (A)
TC7 cells were cotransfected with PALUC and pw2t, which is known to
express both ST and 17KT, or pw2tDL, in which the ST splice donor is
absent but 17KT expression is unaffected. (B) TC7 cells were cotrans-
fected with PALUC and either pw2tDL or pw2tDLRb-, a mutation in the
LXCXE Rb-binding motif, to show the dependence of transactivation on
this motif when ST is not expressed. For both A and B, cell lysates were
extracted 48 h post-transfection. Results are expressed relative to the
pGEM3 control plasmid.
Fig. 3. Transactivation of the cyclin A promoter by ST or 17KT
individually. (A) TC7 cells were cotransfected with PALUC and cDNAs
for either ST (pw2t cDNA) or the 17KT protein. The dependence of 17KT
transactivation on the dnaJ domain was tested using 17KT 43/45. (B) TC7
cells were cotransfected with PALUC and plasmids that encode cDNAs for
WT ST, the PP2A binding mutant C103S, or the dnaJ domain mutant P43L/
K45N. For both A and B, cell lysates were collected 48 h post-transfection.
Results are expressed relative to the pGEM3 control.
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promoter.
Transactivation of the cyclin A promoter by both 17KT
and ST required that we re-interpret earlier mutational
studies. In particular, it was not possible to determine
whether the PP2A-binding region of ST played any role
because plasmids that carried mutations in this region
continued to express WT 17KT. Therefore, cDNA con-
structs which express only ST were used to explore
mechanisms behind the transactivation of the cyclin A
promoter by ST, the focus of the rest of this study. As shown
in Fig. 3B, the transactivation of the cyclin A promoter by
ST alone was eliminated by C103S mutation, clearly
demonstrating the requirement for the interaction of ST
with PP2A. In contrast, the dnaJ domain mutation had only
a slight effect on transactivation of the cyclin A promoter by
ST. Thus, earlier reports describing a role of the dnaJ
domain in cyclin A transactivation reflected the activity of
the 17KT protein and not that of ST itself.
The cell cycle regulation of the cyclin A promoter has
been previously studied in detail (Henglein et al., 1994).
This study defined the cell cycle-regulated regions in the 8.1
kb promoter by testing a series of truncated promoter/
luciferase constructs for their responsiveness at the onset of
S-phase. The promoter proximal sections of this promoter
are diagrammed in Fig. 4A. Initial studies tied cell cycleregulation of the cyclin A promoter to a 180-bp region
consisting of 117 nucleotides upstream from the tran-
scription start site and 30 nucleotides downstream (Henglein
et al., 1994). Within this region were an ATF site (70) and
a variant E2F site (37). A subsequent study established
that the variant E2F site binds to nuclear proteins extracted
from cells at G1/S and that cell cycle regulation is lost when
this E2F site is mutated from TCGCG to AGCTT (Schulze
et al., 1995). This site will be referred to as the cell cycle-
regulated E2F site or E2F* for the rest of this discussion.
To ascertain which regions of the cyclin A promoter
respond to ST, each of the truncated cyclin A promoter/
luciferase constructs was screened for transactivation in
response to pw2t cDNA. Although actual data with these
original constructs are not shown here, the smallest ST-
responsive promoter fragment (215 to +245) was one that
contained three Sp1 sites, an ATF site and E2F*, along with
minor transcription factor binding sites that fall between +11
(transcription start site) and +245. Mutation of the three Sp1
sites in this fragment did not eliminate ST-induced trans-
activation (data not shown).
Once these initial experiments were conducted using the
available PALUC truncations, smaller regions of the
promoter were cloned by PCR to better define the ST-
responsive elements. The shortest derivative that responded
Fig. 5. Role of the cell cycle-regulated E2F site in ST transactivation of the
cyclin A promoter. TC7 cells were transfected with a reporter vector which
contains the 7 kb cyclin A promoter region up to +11, or the variant in
which the cell cycle-regulated E2F site was mutated. Results are expressed
relative to the pGEM3 control which was set to 1.
Fig. 4. ST transactivation of a minimal cyclin A promoter. (A) The diagram
shows major transcription factor binding sites in the cyclin A promoter,
from an AP1 site at about 300 (relative to the transcription start site) to the
start of translation at +245. The solid line marks the limits of the minimal
small-t-responsive promoter construct used in B. The arrow above the line
indicates the start of transcription. (B) Luciferase activity was measured
from a construct that contains cyclin A promoter sequences 117 to +30 as
diagrammed in A. TC7 cells were cotransfected with this reporter and
plasmids that expressed WT ST, C103S, or P43L/K45N. Cell lysates were
collected 48 h post-transfection. Results are expressed relative to the
pGEM3 control which was set at 1. The background levels differ because
the mutation leads to derepression of the promoter.
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construct contains only an ATF site and the cell cycle-
regulated E2F site described in earlier studies. As shown in
Fig. 4B, this minimal promoter was readily transactivated
by the pw2t cDNA plasmid, and transactivation was
strongly dependent on the interaction of ST with PP2A.
Although the mutated dnaJ domain of ST slightly reduced
transactivation, the reduction was modest and far less
striking than that of the PP2A mutation.
Results with this minimal promoter have several impli-
cations. First, transactivation of the cyclin A promoter by
ST does not depend on the Sp1 sites. Others have reported
that ST has the ability to stimulate transcription of other
promoters via Sp1 (Garcia et al., 2000). Apparently, the Sp1
sites are not the major ST-responsive sequences in the cyclin
A promoter. Second, any minor transcription factor binding
sites found between +30 and +245 of the promoter are not
required. Finally, the role of the ATF sequence at 77 is of
interest. Mutations of this site reduced basal transcription so
dramatically that it was difficult to monitor ST responsive-
ness, although experiments reproducibly showed greater
activity from ATF mutant promoters when ST was present
(data not shown). Taken together, approaches using trun-
cated promoters suggested that the cell cycle-regulated E2F
site was the primary target for regulation by ST.
In order to fully explore the responsiveness of the E2F*
site to ST, the point mutations ablating this site wereintroduced into a cyclin A promoter/luciferase construct.
The backbone promoter used contains over 7 kb of upstream
sequences relative to the transcription start site but only 11
nt downstream. It is nearly identical to the promoter used in
Figs. 2 and 3, except that it lacks a few hundred nucleotides
downstream from the transcription start site. These sequen-
ces were not required for cell cycle regulation (Henglein et
al., 1994) or for ST transactivation. As shown in Fig. 5, the
WT promoter, E2F*wt-LUC, was fully responsive to ST
and, although not shown here, this response was dependent
on the PP2A binding ability of ST. In contrast, E2F*mut-
LUC showed significantly less transactivation by ST. To
produce this mutant, the E2F sequence at 37 was changed
from tagTCGCGgga to tagAGCTTgga (Schulze et al.,
1995). The nearly full-length promoter used in this experi-
ment contains many other transcription factor binding sites
(AP1, Sp1, ATF) that are potential targets for PP2A
regulation, yet mutation of the single cell cycle-regulated
E2F site had a pronounced effect. The use of this 7KB
promoter, rather than a truncated derivative, highlights the
importance of the cell cycle-regulated E2F site in ST
responsiveness.
In summary, it appears that the sequences in the cyclin A
promoter that are responsible for cell cycle regulation and
those targeted by ST are identical. It is intriguing that the
variant E2F site has been found to be regulated, at least in
part, by the cki p27 which regulates the presence of cyclin E-
cdk2 complexes formed at this site in G1 (Zerfass-Thome et
al., 1997). This raises the possibility that ST, which has been
shown to decrease levels of p27 in cells (Porras et al., 1999),
is not directly acting at the promoter but that it is able to
increase transcription from this promoter by inhibiting p27.Materials and methods
Cell culture
All transactivations were performed using CV1 monkey
kidney cells, TC7 clone, kindly provided by Dr. M. Judith
C. Skoczylas et al. / Virology 332 (2005) 596–601600Tevethia. Cells were grown in Dulbecco’s modified Eagle’s
medium (DME) containing 5% fetal bovine serum.
Plasmids
Derivatives of the p2wt plasmids (Chang et al., 1985)
were described previously (Boyapati et al., 2003; Porras et
al., 1996). Luciferase reporters containing various deriva-
tives of the cyclin A promoter have also been described
(Henglein et al., 1994; Schulze et al., 1995). The
minimally responsive promoter described in Fig. 3 was
constructed by cloning cyclin A sequences obtained by
polymerase chain reaction upstream of a minimal TATA
box in the luciferase-expression plasmid TK81 (Watanabe
et al., 1996).
Transactivation
TC7 cells were plated 16–18 h prior to transfection
using 4.5  105 cells per 60 mm dish then transfected as
described (Cavender et al., 1999). DNA (10 Ag total) was
suspended in buffer then adjusted to a final concentration
of 500 Ag/ml DEAE-dextran. This solution was then added
to twice-washed cells for 20 min at room temperature. All
plasmids used were prepared by double-banding in cesium
chloride-ethidium bromide gradients. The experiments
described here were done using 2.5 Ag luciferase reporter
construct, 5 Ag ST or 17KT expression plasmid, and 2.5 Ag
salmon-sperm DNA.
Luciferase assays
Luciferase assays were performed using the Luciferase
Assay System (Promega) and luminescence was read
using a Bio-TEK Synergy HT Multidetection Microplate
Reader. The concentrations of protein extracts were
determined using the Bio-Rad reagent, and equal amounts
of each lysate were used in the assay. Quadruplicate
aliquots of each extract were assayed in each experiment
and used to determine statistical significance. In addition,
each experiment was repeated at least three times, and the
experiments shown are representative of the replicate
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